Semantic Scholar uses AI to extract papers important to this topic.
OBJECTIVES:NCX-1000 (2(acetyloxy) benzoic acid-3(nitrooxymethyl)phenyl ester) is an nitric oxide (NO)-releasing derivative of… Expand EDITORIAL EXPRESSION OF CONCERN. PNAS is publishing an Editorial Expression of Concern regarding the following three articles: (i… Expand Nonalcoholic steatohepatitis (NASH) is a common and potentially severe form of liver disease. This study aimed to determine the… Expand NCX‐1000, (3α, 5β, 7β)‐3,7‐dihydroxycholan‐24oic acid[2‐methoxy‐4‐[3‐[4‐(nitroxy)butoxy]‐3‐oxo‐1‐propenyl]phenyl ester, is a… Expand Portal hypertension, a life threatening complication of liver cirrhosis, results from increased intrahepatic resistance and… Expand Recent advances in the knowledge of the pathophysiology of portal hypertension show that cirrhotic liver exhibits endothelial… Expand BACKGROUND/AIMS
A decreased intra-hepatic nitric oxide (NO) production participates on the pathogenesis of portal hypertension in… Expand BACKGROUND/AIMS
We studied whether acute administration of NCX-1000, a nitric oxide (NO)-releasing derivative of ursodeoxycholic… Expand Portal hypertension resulting from increased intrahepatic resistance is a common complication of chronic liver diseases and a… Expand Caspases are key mediators in liver inflammation and apoptosis. In the present study we provide evidence that a nitric oxide (NO… Expand